Expert review of pharmacoeconomics & outcomes research
-
Expert Rev Pharmacoecon Outcomes Res · Jun 2014
Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain.
Pain is a symptom of cancer and is categorized in two forms: background pain to be treated with analgesics, and breakthrough cancer pain (BTcP), which needs drug treatment on demand. We present a cost-effectiveness analysis of transnasal fentanyl citrate as an alternative to morphine. ⋯ Transnasal Fentanyl citrate is cost-effective, therefore represents a good investment in health.